Received: 9 May 2021
Accepted: 31 August 2021
First Online: 12 September 2021
: The PATH study was approved by the Alfred Hospital Human Research Ethics Committee (79/12) and the Victorian Government Department of Justice and Community Safety Human Research Ethics Committee (CF/14/10169). All participants completed informed written consent to participant in the study. The study was undertaken in accordance with the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research.
: Not applicable.
: MS has received investigator-initiated funding from Gilead Sciences, AbbVie, and Bristol Myers Squibb for research unrelated to this work. PD has received investigator-driven funding from Gilead Sciences for work related to hepatitis C treatment and an untied educational grant from Indivior for work related to the introduction of buprenorphine/naloxone into Australia. He has also served as an unpaid member of an Advisory Board for an intranasal naloxone product. The remaining authors declare that they have no conflicts of interest.